GENEMEDICS APP

GENEMEDICS NUTRITION

KPV

Author: Dr. George Shanlikian, M.D.  |   Last Updated: November 25th, 2024

Share This Page

Book a Free Consultation

Overall Health Benefits of KPV

KPV benefits include anti-inflammatory properties, aiding in wound healing, and reducing symptoms of inflammatory bowel disease. Additionally, it shows potential in enhancing skin health and mitigating conditions such as psoriasis and acne.

  • Treats a Wide Array of Inflammatory Conditions [2-24]
  • Improves Wound Healing [25-30]
  • Improves Skin Health [31-45]
  • Strengthens the Immune System [25, 26, 46-73]
  • Protects Against Nerve Damage [74-97]
  • Protects Against Stroke [98-111]

Key Takeaways

  • Anti-inflammatory Properties: KPV is known for its strong anti-inflammatory effects, making it useful in treating various inflammatory conditions.
  • Wound Healing: It aids in accelerating wound healing, promoting faster recovery of damaged tissues.
  • Inflammatory Bowel Disease: KPV has shown promise in reducing symptoms associated with inflammatory bowel disease, offering potential relief for patients.
  • Skin Health: The peptide can enhance skin health, helping to treat conditions like psoriasis and acne.
  • Therapeutic Potential: KPV’s benefits make it a promising candidate for further research and development in therapeutic applications across different medical fields.

What is KPV?

KPV is a tripeptide (Lysine-Proline-Valine) that possesses potent anti-inflammatory properties. It’s a C-terminal tripeptide of α-MSH (alpha-Melanocyte-stimulating hormone). Peptides like KPV often act as hormones and relay information from one tissue through the blood to another via biological messengers. Whether given orally or in the form of injections, the KPV tripeptide has the potential to treat immune-mediated inflammatory conditions such as dermatitis, bowel diseases, allergic asthma, and arthritis.

How KPV Works


KPV exerts its anti-inflammatory function inside cells, where it inactivates inflammatory pathways. KPV enters the cell and interacts directly with inflammatory signalling molecules inside the cell. It enters the nucleus of the cell and, once there, can inhibit the interaction of inflammatory substances and molecules. In addition to its anti‐inflammatory effect, KPV also has antimicrobial effects against pathogens such as S. aureus and C. albicans.

Chemical Structure of KPV

Research on KPV

A. Treats a Wide Array of Inflammatory Conditions

IMG
Interestingly, KPV appears to only have an effect in the setting of inflammation and it has almost no effect in normal tissue. The main reason for this is that KPV enters the cells using a transporter that is unregulated in case of inflammation. This suggests that the peptide may serve as an effective or preventive medication in inflammatory conditions. If taken regularly, KPV will be available when necessary and the body can simply excrete it if inflammation and other symptoms are not present.

Another amazing advantage of KPV is that, unlike alpha-Melanocyte-stimulating hormone, it does not cause skin pigmentation. [1] Moreover, KPV retains most of the anti-inflammatory properties of alpha-Melanocyte-stimulating hormone but without unpleasant side effects. Another appealing aspect of KPV is that it can be administered via different routes – oral, intravenous (through the veins), subcutaneous (between the muscle and fat), and transdermal (into the dermis of the skin). This allows KPV to be administered in different body areas with a higher level of safety and efficacy.

An overwhelming body of clinical evidence suggests that KPV exerts its strong anti-inflammatory properties through various important mechanisms:

  1. In a mice model of colitis (colon inflammation), oral administration of KPV (added to drinking water) inhibited the activation of NF-κB and MAP kinase inflammatory signaling pathways and reduced pro-inflammatory cytokine secretion. [2]
  2. A 2001 study published in Biochem Pharmacology found that KPV exerts its anti-inflammatory activities through inhibition of NF-kappaB translocation and activation of MC(1) receptor/cAMP. [3-4]
  3. In an animal model of colitis, KPV significantly reduced intestinal inflammation. [5-6]
  4. As a C-terminal tripeptide of α-MSH, KPV fights inflammation by inhibiting tumor necrosis factor-α stimulated NF-κB activity and suppressing antigen-induced lymphocyte proliferation. [7-8]
  5. A study published in the Journal of Federation of American Societies for Experimental Biology found that KPV suppresses inflammation through modulation of physiological responses in host defense. [9]
  6. A 2003 study published in the Journal of Pharmacology and Experimental Therapeutics found that KPV exhibits its anti-inflammatory effect through inhibition of IL-1beta functions. [10]
  7. A 2006 study published in the Basic & Clinical Pharmacology & Toxicology found that KPV fights inflammation by stimulating cAMP generation in a concentration-dependent way. [11]
  8. One study found that KPV combats inflammation by significantly inhibiting NF-kappaB-luciferase activity. [12]
  9. A 2010 study published in Advances in Experimental Medicine and Biology reported that KPV has significant similarities to the anti-inflammatory signaling of α-MSH. [13]
  10. Several studies have shown a significant reduction of pro‐inflammatory substances such as IL1 β, IL6, TNFα, IL8, Groα, and interferon γ (IFNγ) following KPV treatment. [14-15]
  11. A cell study found that KPV produced antibodies against the inflammatory IL10. [16]
  12. Studies also show that KPV reduces inflammation through inhibition of inflammatory cell adhesion and transmigration. [17-18]
  13. In murine models of colitis, KPV treatment showed significant anti-inflammatory effects which suggest that it can be an important therapeutic option in treating inflammatory bowel disease. [19]
  14. In a mice model of ulcerative colitis, oral administration of KPV loaded into hyaluronic acid (HA)-functionalized polymeric nanoparticles (NPs) was effective in alleviating intestinal inflammation. [20]
  15. In mice, topical administration of KPV in chemotherapy-induced oral mucositis resulted in improved healing due to its anti-inflammatory and antibacterial properties. [21]
  16. In an imiquimod-induced psoriasis mouse model, the application of a gel containing alpha-MSH resulted in a reduction in psoriasis-associated inflammation. [22]
  17. Studies reported that most of the anti-inflammatory activities of alpha-MSH can be attributed to its C-terminal tripeptide KPV. [23-24]

B. Improves Wound Healing

IMG
The potent anti-inflammatory properties of KPV may play a role in speeding up the wound healing process. In addition, since KPV does not cause skin pigmentation, this makes it a good candidate for improving wound healing while avoiding unpleasant skin changes. Another mechanism that is thought to contribute to faster wound healing is the immune-boosting effects of KPV, which helps lower the risk of infection during the regeneration process.

The beneficial effects of KPV on wound healing are backed by a number of studies:

  1. Studies found that alpha-MSH peptides can speed up wound healing by enhancing the antimicrobial activity of human neutrophils and through their antifungal effects. [25-26]
  2. In young adult mice with two circular through-and-through holes (6.5 mm diameter), the injection of 1 mg/kg of α-MSH reduced the scar area and improved the organization of the collagen fibers. [27]
  3. In rats with liver injury caused by surgery, a single intravenous injection of α-MSH increased the replication of liver cells. [28]
  4. In rats that had undergone heart transplantation, α-MSH preserved heart function and prolonged the survival of tissue graft. [29]
  5. In rats with acute bleomycin-induced lung injury, α-MSH peptide treatment reduced inflammation and prevented alterations in genes involved in lung fluid homeostasis. [30]

C. Improves Skin Health

IMG
The anti-inflammatory effects of KPV make it an ideal treatment for various inflammatory skin conditions. Furthermore, the immune-boosting effects as well as antimicrobial and antifungal properties of this peptide may play a role in improving skin health.

Evidence suggests that KPV has the potential to treat unpleasant skin conditions:

  1. In mice with experimental contact dermatitis, KPV suppressed the skin inflammatory response. [31-34]
  2. In human subjects, the application of KPV cream reduced nickel‐induced contact eczema. [35]
  3. KPV also suppresses antigen-induced lymphocyte proliferation in humans, resulting in healthier and smoother skin. [36]
  4. A 2012 study published in the Journal of Allergy and Clinical Immunology found that KPV acts as a natural anti-allergic basophil-response modifier. [37]
  5. A study published in the Archives of Dermatological Research reported that KPV regulates interleukin-10 production by human keratinocytes (skin cells), a mechanism that prevents skin inflammation. [38]
  6. In mice, the application of KPV on the skin suppressed contact hypersensitivity responses. [39]
  7. Several studies also found that KPV is capable of suppressing the production of intercellular adhesion molecule-1 (ICAM-1) induced by pro-inflammatory stimuli such as TNF-α, IFN-γ, or LPS in the skin. [40-45]

D. Strengthens the Immune System

Aside from its potent anti-inflammatory properties, studies show that KPV may help boost immune function by positively affecting the production of immune system cells and other mechanisms:

  1. Studies found that alpha-MSH peptides can enhance the antimicrobial activity of human neutrophils and can help fight fungi such as Cryptococcus neoformans. [25-26]
  2. As a C-terminal tripeptide of α-MSH, studies found that KPV has potent antipyretic activity (lowers body temperature) in experimental fever. [46-55]
  3. Studies show that KPV prevents fever by targeting the hypothalamus, the brain region that controls temperature, and by reducing pyrogens (substances that cause fever). [56-62]
  4. A 2007 study published in Gene Therapy found that KPV treatment was associated with a high frequency of CD4+CD25+ regulatory T cells. [63]
  5. In rats, KPV injections twice daily significantly reduced the clinical and histological signs of adjuvant-induced arthritis. [64]
  6. In animal models of human autoimmune inflammatory eye diseases such as uveitis or retinitis, KPV significantly reduced symptoms and inflammatory substances. [65-69]
  7. In an animal model of experimentally induced acute pancreatitis, KPV treatment reduced pancreas islet cell apoptosis (programmed cell death. [70-72]
  8. In rabbits with fever induced by intravenous administration of leukocytic pyrogen, central (0.5-2.0 mg) and peripheral (2-200 mg) administration of KPV reduced fever. [73]

E. Protects Against Nerve Damage

As a C-terminal tripeptide of α-MSH, KPV exerts protective effects against various forms of nerve damage, suggesting that it can help combat the effect of aging and other medical conditions on nerve health:

  1. In neonatal rats with nerve injury, KPV effectively induced sciatic nerve regeneration. [74-75]
  2. A cell study found that KPV stimulated the growth of the long threadlike part of a nerve cell called an axon. [76]
  3. In a rat model of spinal cord injury, the application of α-MSH cream shortly after trauma in high doses induced nerve protection. [77]
  4. In cultured rat brain cells, treatment with 10 nM α-MSH protected against cisplatin-induced neurotoxicity. [78-79]
  5. A cell study also found that α-MSHprotects against nerve damage by blocking signals involved in programmed cell death. [80 -81]
  6. Studies found that α-MSH protects nerve cells against ultraviolet radiation-induced apoptosis and DNA damage. [82-83]
  7. Studies show that α-MSH may help protect nerve cells through its anti-scarring properties. [84-91]
  8. In rats, local delivery of α-MSHcan increase postlesional repair of nerve. [92-93]
  9. Rat studies also show that α-MSH treatment can significantly improve the neurological and electrophysiological function of the damaged spinal cord. [94-97]

F. Protects Against Stroke

Because KPV and α-MSH share similar properties, they may exert the same beneficial effects. There’s increasing evidence that supports that these peptides may be a therapeutic option in stroke:

  1. α-MSH (1 mg/kg) was shown to improve the recovery of animals with stroke, especially when given before and during the 20-minute ischemia (reduced blood flow to the brain). [98]
  2. When given before the start of the ischemia and again 1 hour after reperfusion (restoration of blood flow), α-MSH prevents further occlusion and inflammation of the artery. [99]
  3. Several studies suggest that α-MSH exerts its protective mechanism against ischemic brain damage by reducing the brain levels of pro-inflammatory cytokines. [100-104]
  4. A 2003 study published in the European Journal of Pharmacology reported that subcutaneous injection of α-MSH appears to significantly reduce the size of infarct (dead tissue caused by reduced blood flow). [105]
  5. Several studies also found that α-MSH can help protect against heart and kidney problems associated with stroke. [106-111]

KPV Peptide Side Effects

KPV side effects are very uncommon. There have been some side effects associated with the use of this drug wherein the patient had one of the issues listed below at some point while being on KPV. However, these side effects weren’t confirmed to be associated with the treatment and could have been a coincidence and not related to the use of KPV. Despite this, it was listed as a side effect associated with KPV even though these associated side effects are very uncommon.

Side effects associated with KPV may include the following:

  • Diarrhea
  • Headache
  • Nausea
  • Vomiting

KPV Peptide Dosage

Determining the appropriate KPV peptide dosage is crucial for maximizing its therapeutic benefits while minimizing potential side effects. The optimal dosage can vary depending on the specific condition being treated, the patient’s overall health, and their response to the peptide. Typically, KPV is administered in low doses, as even small amounts can yield significant anti-inflammatory and healing effects. Researchers often start with conservative dosages in clinical trials to ensure safety and gradually adjust based on the observed outcomes.

For inflammatory conditions such as inflammatory bowel disease and skin disorders, KPV dosages need careful calibration. In such cases, dosages are often tailored to the severity of the condition and the patient’s response to initial treatments. For example, patients with more severe symptoms might require higher doses or more frequent administration to achieve the desired therapeutic effect. Conversely, patients with milder symptoms might benefit from lower doses, which can still effectively reduce inflammation and promote healing.

It’s essential to monitor patients closely when determining the optimal KPV peptide dosage. Regular assessments and adjustments help to ensure that the peptide’s benefits are maximized while minimizing any adverse reactions. Healthcare providers typically use a combination of patient feedback, clinical markers, and imaging studies to guide dosage adjustments. By doing so, they can provide personalized treatment plans that enhance the effectiveness of KPV while safeguarding patient health.

KPV Peptide Cancer

KPV peptide has garnered attention for its potential in cancer treatment due to its anti-inflammatory and immunomodulatory properties. Inflammation is a known facilitator of tumor growth and metastasis, and KPV’s ability to reduce inflammation could play a significant role in hindering cancer progression. By mitigating the inflammatory environment that supports cancer cells, KPV could slow down tumor growth and improve the effectiveness of other cancer therapies.

Moreover, KPV’s influence on the immune system is another promising aspect in the context of cancer. The peptide can modulate immune responses, potentially enhancing the body’s natural ability to recognize and attack cancer cells. This immunomodulatory effect might work synergistically with existing immunotherapies, offering a multifaceted approach to combating cancer. The ability to boost immune surveillance and response is critical in preventing the spread and recurrence of malignancies.

Early research and clinical trials are essential to fully understand the scope of KPV’s efficacy in cancer treatment. While current studies are encouraging, more comprehensive investigations are needed to determine the optimal dosing, delivery methods, and specific cancer types that could benefit the most from KPV therapy. If these studies prove successful, KPV could become an integral part of cancer treatment regimens, providing a novel and effective approach to managing the disease.

KPV Peptide Injection

KPV peptide injection is gaining attention in the medical community for its potent anti-inflammatory and healing properties. Derived from the alpha-MSH hormone, KPV is a tripeptide composed of lysine, proline, and valine. When administered via injection, KPV can target specific areas of inflammation or tissue damage, providing localized relief and promoting faster recovery. This makes it particularly valuable in treating conditions like inflammatory bowel disease (IBD), where inflammation is a significant concern.

One of the most promising aspects of KPV peptide injection is its potential in dermatological applications. The peptide has shown efficacy in treating skin conditions such as psoriasis and acne by reducing inflammation and accelerating the healing process. Its ability to enhance skin health extends beyond cosmetic benefits, offering therapeutic relief for patients suffering from chronic skin disorders. This has led to increased interest in KPV as a versatile treatment option in both clinical and aesthetic dermatology.

Furthermore, KPV peptide injection is being explored for its broader therapeutic potential. Its anti-inflammatory and healing properties could be beneficial in managing a range of inflammatory diseases and injuries. By targeting the underlying inflammatory processes, KPV injections could provide a novel approach to treatment, reducing the reliance on traditional medications that often come with significant side effects. As research continues, the scope of KPV’s applications is expected to expand, highlighting its potential as a powerful tool in modern medicine.

KPV Peptide Capsules

KPV peptide capsules are an innovative form of delivering the KPV peptide, known for its potent anti-inflammatory and healing properties. Encapsulating KPV ensures its stability and enhances its bioavailability, allowing the peptide to be effectively absorbed and utilized by the body. This oral administration method offers a convenient and non-invasive alternative to injections, making it more accessible for daily use.

The benefits of KPV peptide capsules are particularly significant for individuals suffering from chronic inflammatory conditions. These capsules can help reduce inflammation, promote wound healing, and alleviate symptoms associated with inflammatory bowel disease, psoriasis, and acne. By taking KPV in capsule form, users can potentially manage their conditions more efficiently, improving their quality of life without the need for more invasive treatments.

Furthermore, KPV peptide capsules hold promise for broader therapeutic applications. Their ease of use and potent effects make them an attractive option for ongoing research in various medical fields. As more studies are conducted, the potential for KPV peptide capsules to become a mainstream treatment for a range of inflammatory and autoimmune disorders grows, highlighting the importance of continued exploration and development in this area. These capsules are specifically designed to address inhibited immune responses.

KPV Peptide Buy

When considering the purchase of KPV peptide, it’s essential to understand its therapeutic potential and benefits. KPV is a synthetic peptide known for its anti-inflammatory properties and effectiveness in promoting wound healing. It has shown promise in treating various inflammatory conditions, including inflammatory bowel disease, psoriasis, and acne. These benefits make KPV an attractive option for individuals looking to manage chronic inflammation and improve their overall skin health.

Before purchasing KPV peptide, it’s crucial to ensure you are buying from a reputable source. Since KPV is still primarily used in research settings, finding a reliable supplier that offers high-quality, pure peptides is vital. Look for suppliers with positive reviews, proper certifications, and transparency regarding their manufacturing processes. Consulting with a healthcare professional before starting any new treatment, including KPV, is also advisable to ensure it is appropriate for your specific needs. It’s especially important to consider the impact of KPV peptide on colonic cells, as its effects may vary depending on cell type and application.

Additionally, understanding the proper usage and dosage of KPV peptide is essential for achieving the desired results. Follow the guidelines provided by the supplier and consult scientific literature or medical professionals to determine the best administration methods. With careful consideration and responsible use, purchasing KPV peptide can be a beneficial step toward managing inflammation and enhancing overall health. It’s important to note that KPV peptide targets major pathogens called inflammation at its source, contributing to its effectiveness. Moreover, KPV peptide has been shown to modulate inhibited immune responses, further enhancing its therapeutic potential in various inflammatory conditions.

KPV in Inflammatory Bowel Diseases

KPV, a potent anti-inflammatory peptide, has garnered significant interest in the treatment of inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis. These chronic conditions are characterized by persistent inflammation of the gastrointestinal tract, leading to symptoms like abdominal pain, diarrhea, and fatigue. KPV’s ability to modulate the immune response and reduce inflammation makes it a promising therapeutic candidate for managing these debilitating diseases. KPV targets major pathogens called the immune response and reduce inflammation makes it a promising therapeutic candidate for managing these debilitating diseases.

Recent studies have demonstrated that KPV possesses significant anti-microbial properties, effectively decreasing inflammatory markers in the gut, thereby alleviating the symptoms of IBD. By targeting key pathways involved in the inflammatory process, KPV’s anti-microbial properties help to restore the integrity of the intestinal lining and promote mucosal healing. This not only improves the patient’s quality of life but also reduces the risk of complications associated with prolonged inflammation, such as strictures, fistulas, and colorectal cancer.

Furthermore, KPV’s potential extends beyond symptom management to include long-term disease modification. Its anti-inflammatory properties, coupled with its potential as melanocortin peptides future therapeutics, could help in maintaining remission and preventing flare-ups in IBD patients. Ongoing clinical trials and research are exploring the optimal delivery methods and dosing regimens for KPV, aiming to maximize its therapeutic benefits while minimizing side effects. As our understanding of KPV’s mechanisms and effects deepens, it holds the promise of becoming an integral part of the treatment arsenal for inflammatory bowel diseases.

KPV: A Potent Anti-inflammatory Peptide

KPV, a tripeptide consisting of the amino acids lysine, proline, and valine, has garnered significant attention for its potent anti-inflammatory properties. This peptide’s ability to mitigate inflammation makes it a promising candidate for treating a variety of inflammatory conditions. In particular, KPV has shown effectiveness in reducing the severity of skin-related issues such as psoriasis and acne, where inflammation plays a crucial role in the manifestation of symptoms. By targeting the inflammatory pathways, KPV helps to alleviate redness, swelling, and discomfort associated with these conditions. Recent studies on wound healing show kpv significantly decreased inflammation that its anti-inflammatory properties contribute to faster recovery times and improved healing outcomes. In clinical trials, topical applications of KPV have demonstrated significant reductions in inflammation markers, highlighting its potential as a therapeutic agent for inflammatory skin disorders.

Beyond skin health, KPV has demonstrated potential benefits in the management of inflammatory bowel disease (IBD). In experimental models, KPV administration has led to a reduction in inflammation within the gastrointestinal tract, providing relief from the debilitating symptoms of IBD, such as abdominal pain, diarrhea, and weight loss. This makes KPV a valuable asset in the therapeutic arsenal for IBD patients, offering a novel approach to managing the chronic inflammation that characterizes these disorders. Moreover, studies suggest that wound healing shows kpv significantly decreased inflammation, making it a promising candidate for therapeutic development in the context of IBD.

Moreover, KPV’s role as a naturally derived peptide in wound healing further underscores its significance as an anti-inflammatory agent. By promoting a balanced inflammatory response, KPV, a naturally derived peptide, facilitates the healing process, ensuring that wounds close more efficiently and with less scarring. This property is particularly beneficial in clinical settings where accelerated wound healing can significantly improve patient outcomes. The diverse applications of KPV, a naturally derived peptide, in inflammation-related conditions highlight its potential as a versatile and powerful therapeutic peptide.

KPV in Wound Healing

KPV, known for its therapeutic properties, plays a pivotal role in wound healing. Research indicates that KPV enhances the wound healing process when administered orally by promoting cell proliferation and migration at the wound site. This peptide stimulates collagen synthesis, which is essential for the structural integrity of the skin when administered orally and facilitates the formation of new tissue. By accelerating the closure of wounds and reducing inflammation when administered orally, KPV supports faster recovery and minimizes the risk of infection.

In clinical studies, KPV has demonstrated significant potential in improving wound healing outcomes. Its ability to modulate inflammatory responses and enhance angiogenesis contributes to more efficient tissue repair, reducing scar prominence appears. Moreover, KPV’s anti-inflammatory effects help to create a favorable environment for healing, reducing healing times and improving overall wound closure rates, reducing scar prominence appears. These findings underscore KPV’s therapeutic promise in managing various types of wounds, from acute injuries to chronic ulcers, reducing scar prominence appears.

As a peptide with multifaceted benefits, KPV significantly inhibited not only accelerates the healing of superficial wounds but also shows promise in treating complex wounds that are often challenging to manage. Its mechanism of action includes promoting the migration of keratinocytes and fibroblasts, essential for rebuilding the skin barrier. Clinicians are increasingly exploring KPV’s potential in combination therapies and wound care formulations to optimize treatment outcomes and enhance patient recovery. KPV significantly inhibited Clinicians are increasingly exploring KPV’s potential in combination therapies and wound care formulations to optimize treatment outcomes and enhance patient recovery.

Share This Page

FAQ

What is KPV peptide for?

KPV peptide, known for its therapeutic properties, including promoting wound healing, reducing inflammation, and potentially aiding in the treatment of conditions like inflammatory bowel disease and skin disorders, shows kpv in various medical applications. This peptide’s ability to reduce infection is particularly notable in wound care, where it helps maintain a sterile environment and accelerate wound healing shows kpv processes. Scientific research has shown that KPV peptide holds promise in various medical applications, demonstrating its effectiveness in clinical trials and experimental studies wound healing shows kpv.

Can KPV be taken orally?

No, KPV peptide is typically not administered orally due to its structure and the likelihood of degradation in the digestive system. It is usually administered through topical application or injection to achieve cosmetic results and reduce infection. Topical application or injection of KPV peptide is effective in achieving cosmetic results and reducing infection.

What caliber is a KPV?

KPV is not measured in calibers. It refers to a specific peptide sequence where cosmetic results occur and is not related to firearms or ammunition. The study of KPV aims to reduce infection, ensuring that cosmetic results occur in medical contexts. Researchers are investigating the potential of KPV in treating colon cancer.

What is the difference between KPV and KPVT?

KPV and KPVT are different peptide sequences. KPV typically refers to a specific sequence with known therapeutic effects for serious wounds, while KPVT might refer to a different peptide variant or modification that can modulate collagen metabolism in cases of serious wounds. These peptides are often studied for their potential anti microbial properties, particularly in wound care applications where infection control is crucial.

What does KPV peptide do?

KPV peptide facilitates wound healing by promoting cell proliferation, collagen synthesis, and reducing inflammation, which is crucial for managing conditions like hypertrophic scar. It also shows potential in managing inflammatory conditions and improving skin health, including hypertrophic scar. The peptide’s anti-inflammatory function aids in reducing swelling and promoting healing, making it effective in treating various inflammatory conditions, including hypertrophic scar. Moreover, its anti-inflammatory function supports skin health by calming irritation and enhancing recovery processes, which benefits occur is beneficial for managing hypertrophic scar.

What is KPV peptide for ulcerative colitis?

KPV peptide is being researched for its potential to alleviate symptoms of ulcerative colitis by reducing inflammatory stimulation and promoting gut health. Clinical studies are ongoing to assess its effectiveness in this regard, particularly in modulating anti microbial inflammatory stimulation-induced immune responses. The peptide’s ability to target inflammatory stimulation-induced immune responses could offer new insights into managing ulcerative colitis.

What are the downsides of peptide therapy?

Downsides of peptide therapy may include potential side effects, the need for precise administration methods (like injection or topical application), inhibiting proinflammatory cytokine, and limited oral bioavailability for certain peptides. Additionally, inhibiting proinflammatory cytokine may pose challenges in achieving desired outcomes, as precise targeting is necessary. Finally, inhibiting anti microbial proinflammatory cytokine can be complex due to the specific conditions required for effective peptide delivery and activity. Scar reduction is another area where peptide therapy is being explored, though it also faces similar challenges. Ensuring scar reduction requires precise administration and targeting, which can be difficult to achieve. Nonetheless, advancements in peptide therapy for scar reduction hold promise for more effective treatments in the future.

Is KPV peptide safe?

Current research suggests that KPV peptide is generally safe when used appropriately under medical supervision. However, like any therapeutic agent, it may have potential side effects or interactions that should be monitored. Additionally, KPV peptide inactivates inflammatory pathways, making it a promising option for managing various inflammatory conditions. It is important to consider that while KPV peptide inactivates inflammatory pathways, further research is needed to fully understand its long-term effects. As KPV peptide inactivates inflammatory pathways, healthcare providers should closely monitor its use to ensure patient safety and efficacy. The c terminal peptide fragment also plays a crucial role in the overall function and effectiveness of KPV peptide. Research on the c terminal peptide fragment is ongoing, highlighting its potential in various therapeutic applications. Understanding the c terminal peptide fragment’s interactions and effects is essential for optimizing the use of KPV peptide in medical treatments.

What is KPv peptide for?

KPv peptide likely refers to the same therapeutic applications as KPV, focusing on wound healing, anti-inflammatory effects, and potential treatments for conditions like ulcerative colitis and skin disorders. The drastic inflammatory response in such conditions, which involves the inflamed mucosal layer, can be mitigated by the anti-inflammatory properties of KPv peptide. By targeting the inflamed mucosal layer and the drastic inflammatory response, KPv peptide aids in reducing the severity and symptoms of ulcerative colitis and skin disorders. The inflamed mucosal layer and the drastic inflammatory response are key factors in the effectiveness of KPv peptide in these therapeutic applications.

What does the peptide KPV do?

KPV peptide accelerates wound healing, reduces inflammation, and may have therapeutic applications in treating inflammatory conditions and enhancing skin health. Additionally, KPV supports gut health by modulating inflammatory responses in the digestive system, particularly in colonic epithelial cells. By promoting gut health, especially through the action on colonic epithelial cells, KPV helps in managing conditions like inflammatory bowel disease. Furthermore, its overall impact on gut health, including its effects on colonic epithelial cells, contributes to better systemic health and immune function.

What is the mechanism of KPV?

The mechanism of KPV peptide involves promoting cell proliferation, collagen synthesis, and modulating inflammatory responses, which collectively aid in healing wounds, gut health, and potentially treating inflammatory diseases. By improving gut health, KPV can have a positive impact on overall well-being. Additionally, its role in maintaining gut health and healing wounds contributes to its effectiveness in treating inflammatory diseases. The ability of KPV to promote healing wounds makes it a valuable peptide in both anti microbial medical and research settings.

What are the side effects of topical peptides?

Common side effects of topical peptides may include mild irritation, redness, or sensitivity at the application site. Severe side effects are rare but can include allergic reactions in both intestinal epithelial cells in sensitive individuals. Both intestinal epithelial cells may experience mild irritation, redness, or sensitivity at the application site. Severe side effects are rare but can include allergic reactions in sensitive individuals and in both intestinal epithelial cells. Topical peptides can play a significant role in healing wounds, making it essential to monitor any reactions closely. Using peptides for healing wounds is generally beneficial, but it’s important to be aware of potential side effects. Always consult with a healthcare professional to ensure the safety and efficacy of peptides in healing wounds.

What is KPv peptide?

KPV peptide likely refers to the same peptide sequence as KPV, known for its therapeutic benefits in wound healing, anti-inflammatory properties, and potential applications in treating various medical conditions. KPV significantly decreased inflammation by inhibiting proinflammatory mechanisms. Understanding how KPV interacts with proinflammatory mechanisms is crucial for maximizing its therapeutic potential. Further research on KPV’s ability to modulate proinflammatory mechanisms can provide deeper insights into its effectiveness and safety.

What are peptides for colon cancer?

Peptides used for colon cancer treatment may include those targeting specific receptors or pathways involved in cancer cell growth, angiogenesis, or immune response modulation. They are often part of targeted therapies to speed wound healing reduce infection. Additionally, some peptides may also possess properties that help speed wound healing reduce infection, which can be beneficial in post-surgical recovery. Researchers continue to explore various peptides that not only target cancer cells but also speed wound healing reduce infection to improve overall patient outcomes.

Do injectable peptides really work?

Yes, injectable peptides can be effective in medical treatments where precise delivery is needed, such as hormone therapy, cancer treatment, or targeted drug delivery involving immune cells. Immune cells play a crucial role in enhancing the efficacy of these treatments. Additionally, immune cells can be targeted by injectable peptides to improve therapeutic outcomes.

How much does a peptide injection cost?

The cost of peptide injections can vary widely depending on the specific peptide, dosage, treatment duration, and healthcare provider. Prices can range from hundreds to thousands of dollars per treatment course to fight inflammation. Peptide injections designed to fight inflammation may have different costs compared to other types of peptide therapies. Overall, investing in peptide injections to fight inflammation can lead to significant health benefits, including improved wound healing and reduced infection. Additionally, peptide injections can be particularly effective in wound healing, reducing infection, and promoting faster recovery times. For those dealing with chronic inflammation, peptide injections can be a valuable tool to enhance wound healing, reduce infection, and improve overall health outcomes.

Reference

  1. Brzoska, T., Luger, T. A., Maaser, C., Abels, C., & Böhm, M. (2008). Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine reviews, 29(5), 581–602. https://doi.org/10.1210/er.2007-0027.

  2. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. doi:10.1053/j.gastro.2007.10.026.

  3. Mandrika I, Muceniece R, Wikberg JE. Effects of melanocortin peptides on lipopolysaccharide/interferon-gamma-induced NF-kappaB DNA binding and nitric oxide production in macrophage-like RAW 264.7 cells: evidence for dual mechanisms of action. BiochemPharmacol. 2001;61(5):613-21.

  4. Haddad JJ, Lauterbach R, Saadé NE, Safieh-garabedian B, Land SC. Alpha-melanocyte-related tripeptide, Lys-d-Pro-Val, ameliorates endotoxin-induced nuclear factor kappaB translocation and activation: evidence for involvement of an interleukin-1beta193-195 receptor antagonism in the alveolar epithelium. Biochem J. 2001;355(Pt 1):29-38.

  5. Rajora N, Boccoli G, Catania A, et al. α-MSH modulates experimental inflammatory bowel disease. Peptides. 1997;18:381–385.

  6. Oktar BK, Ercan F, Ye en BC, et al. The effect of α-melanocyte stimulating hormone on colonic inflammation in the rat. Peptides. 2000;21:1271–1277.

  7. Kelly JM, Moir AJ, Carlson K, et al. Immobilized α-melanocyte stimulating hormone 10–13 (GKPV) inhibits tumor necrosis factor-α stimulated NF-κB activity. Peptide. 2006;27:431–437.

  8. Cooper A, Robinson SJ, Pickard C, et al. α-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status. J Immunol. 2005;175:4806–4813.

  9. Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989;3(11):2282-4.

  10. Getting SJ, Schioth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J PharmacolExpTher. 2003;306(2):631-7.

  11. Schiöth HB, Muceniece R, Mutule I, Wikberg JE. New melanocortin 1 receptor binding motif based on the C-terminal sequence of alpha-melanocyte-stimulating hormone. Basic ClinPharmacolToxicol. 2006;99(4):287-93.

  12. Kelly JM, Moir AJ, Carlson K, Yang Y, Macneil S, Haycock JW. Immobilized alpha-melanocyte stimulating hormone 10-13 (GKPV) inhibits tumor necrosis factor-alpha stimulated NF-kappaB activity. Peptides. 2006;27(2):431-7.

  13. Brzoska T, Böhm M, Lügering A, Loser K, Luger TA. Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore. AdvExp Med Biol. 2010;681:107-16.

  14. Luger T A, Scholzen T, Grabbe S. The role of α‐melanocyte stimulating hormone in cutaneous biology. J Invest DermatolSympProc 1997287–93.

  15. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602.

  16. Grabbe S, Bhardwaj R S, Steinert M, Mahnke K, Simon M M, Schwarz T. et al Alpha‐melanocyte stimulating hormone induces hapten‐specific tolerance in mice. J Immunol 1996156473–478.

  17. Bohm M, Eickelmann M, Li Z, Schneider S W, Oji V, Diederichs S. et al Detection of functionally active melanocortin receptors and evidence for an immunoregulatory activity of alpha‐melanocyte‐stimulating hormone in human dermal papilla cells. Endocrinology 20051464635–4646.

  18. Scholzen T E, Sunderkotter C, Kalden D H, Brzoska T, Fastrich M, Fisbeck T. et al Alpha‐melanocyte stimulating hormone prevents lipopolysaccharide‐induced vasculitis by down‐regulating endothelial cell adhesion molecule expression. Endocrinology 2003144360–370.

  19. Klaus Kannengiesser, MD, Christian Maaser, MD, Jan Heidemann, MD, Andreas Luegering, MD, Matthias Ross, MD, Thomas Brzoska, PhD, Markus Bohm, MD, Thomas A. Luger, MD, Wolfram Domschke, MD, Torsten Kucharzik, MD, Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease, Inflammatory Bowel Diseases, Volume 14, Issue 3, 1 March 2008, Pages 324–331, https://doi.org/10.1002/ibd.20334.

  20. Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017 Jul 5;25(7):1628-1640. doi: 10.1016/j.ymthe.2016.11.020. Epub 2017 Jan 28. PMID: 28143741; PMCID: PMC5498804.

  21. Available from https://pubs.rsc.org/en/content/articlehtml/2022/bm/d1bm01466h.

  22. Available from https://www.researchgate.net/publication/284175171_Percutaneous_delivery_of_a_-melanocyte-stimulating_hormone_for_the_treatment_of_imiquimod-induced_psoriasis.

  23. Luger, T. A., & Brzoska, T. (2007). alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Annals of the rheumatic diseases, 66 Suppl 3(Suppl 3), iii52–iii55. https://doi.org/10.1136/ard.2007.079780.

  24. Available from https://www.researchgate.net/publication/7277622_Dissection_of_the_Anti-Inflammatory_Effect_of_the_Core_and_C-Terminal_KPV_-Melanocyte-Stimulating_Hormone_Peptides.

  25. Cutuli, M., Cristiani, S., Lipton, J. M., & Catania, A. (2000). Antimicrobial effects of alpha-MSH peptides. Journal of leukocyte biology, 67(2), 233–239. https://doi.org/10.1002/jlb.67.2.233.

  26. Masman, M. F., Rodríguez, A. M., Svetaz, L., Zacchino, S. A., Somlai, C., Csizmadia, I. G., Penke, B., & Enriz, R. D. (2006). Synthesis and conformational analysis of His-Phe-Arg-Trp-NH2 and analogues with antifungal properties. Bioorganic & medicinal chemistry, 14(22), 7604–7614. https://doi.org/10.1016/j.bmc.2006.07.007.

  27. de Souza, K. S., Cantaruti, T. A., Azevedo, G. M., Jr, Galdino, D. A., Rodrigues, C. M., Costa, R. A., Vaz, N. M., & Carvalho, C. R. (2015). Improved cutaneous wound healing after intraperitoneal injection of alpha-melanocyte-stimulating hormone. Experimental dermatology, 24(3), 198–203. https://doi.org/10.1111/exd.12609.

  28. Lonati, C., Carlin, A., Leonardi, P., Valenza, F., Bosari, S., Catania, A., & Gatti, S. (2013). Modulatory effects of NDP-MSH in the regenerating liver after partial hepatectomy in rats. Peptides, 50, 145–152.

  29. Colombo, G., Gatti, S., Turcatti, F., Sordi, A., Fassati, L. R., Bonino, F., Lipton, J. M., & Catania, A. (2005). Gene expression profiling reveals multiple protective influences of the peptide alpha-melanocyte-stimulating hormone in experimental heart transplantation. Journal of immunology (Baltimore, Md. : 1950), 175(5), 3391–3401. https://doi.org/10.4049/jimmunol.175.5.3391.

  30. Colombo, G., Gatti, S., Sordi, A., Turcatti, F., Carlin, A., Rossi, C., Lonati, C., & Catania, A. (2007). Production and effects of alpha-melanocyte-stimulating hormone during acute lung injury. Shock (Augusta, Ga.), 27(3), 326–333. https://doi.org/10.1097/01.shk.0000239764.80033.7e.

  31. Rheins L A, Cotleur A L, Kleier R S, Hoppenjans W B, Sauder D N, Nordlund J J. Alpha‐melanocyte stimulating hormone modulates contact hypersensitivity responsiveness in C57/BL6 mice. J Invest Dermatol 198993511–517.

  32. Elliott R J, Szabo M, Wagner M J, Kemp E H, MacNeil S, Haycock J W. alpha‐Melanocyte‐stimulating hormone, MSH 11‐13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol 20041221010–1019.

  33. Getting S J, Schioth H B, Perretti M. Dissection of the anti‐inflammatory effect of the core and C‐terminal (KPV) alpha‐melanocyte‐stimulating hormone peptides. J PharmacolExpTher 2003306631–637.

  34. Luger T A, Scholzen T E, Brzoska T, Bohm M. New insights into the functions of alpha‐MSH and related peptides in the immune system. Ann N Y AcadSci 2003994133–140.

  35. Slominski A, Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev 200080979–1020.

  36. Cooper A, Robinson SJ, Pickard C, Jackson CL, Friedmann PS, Healy E. Alpha-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status. J Immunol. 2005;175(7):4806-13.

  37. Bohm M, Apel M, Sugawara K, et al. Modulation of basophil activity: a novel function of the neuropeptide α-melanocyte-stimulating hormone. J Allergy ClinImmunol. 2012;129(4):1085-93.

  38. Redondo P, García-foncillas J, Okroujnov I, Bandrés E. Alpha-MSH regulates interleukin-10 expression by human keratinocytes. Arch Dermatol Res. 1998;290(8):425-8.

  39. Rheins LA, Cotleur AL, Kleier RS, Hoppenjans WB, Saunder DN, Nordlund JJ. Alpha-melanocyte stimulating hormone modulates contact hypersensitivity responsiveness in C57/BL6 mice. J Invest Dermatol. 1989;93(4):511-7.

  40. Morandini R, Boeynaems JM, Hedley SJ, MacNeil S , Ghanem G 1998 Modulation of ICAM-1 expression by α-MSH in human melanoma cells and melanocytes. J Cell Physiol175:276–282.

  41. Kalden DH, Scholzen T, Brzoska T, Luger TA 1999 Mechanisms of the antiinflammatory effects of α-MSH. Role of transcription factor NF-κB and adhesion molecule expression. Ann NY AcadSci 885:254–261.

  42. Scholzen TE, Sunderkötter C, Kalden DH, Brzoska T, Fastrich M, Fisbeck T, Armstrong CA, Ansel JC, Luger TA 2003 α-Melanocyte stimulating hormone prevents lipopolysaccharide-induced vasculitis by down-regulating endothelial cell adhesion molecule expression. Endocrinology 144:360–370.

  43. Bohm M, Eickelmann M, Li Z, Schneider SW, Oji V, Diederichs S, Barsh GS, Vogt A, Stieler K, Blume-Peytavi U, Luger TA 2005 Detection of functionally active melanocortin receptors and evidence for an immunoregulatory activity of α-melanocyte-stimulating hormone in human dermal papilla cells. Endocrinology 146:4635–4646.

  44. Hill RP, MacNeil S, Haycock JW 2006 Melanocyte stimulating hormone peptides inhibit TNF-α signaling in human dermal fibroblast cells. Peptides 27:421–430.

  45. Sarkar A, Sreenivasan Y, Manna SK 2003 α-Melanocyte-stimulating hormone induces cell death in mast cells: involvement of NF-κB. FEBS Lett 549:87–93.

  46. Glyn JR, Lipton JM. Hypothermic and antipyretic effects of centrally administered ACTH (1–24) and alpha-melanotropin. Peptides. 1981;2(2):177-87.

  47. Glyn-ballinger JR, Bernardini GL, Lipton JM. alpha-MSH injected into the septal region reduces fever in rabbits. Peptides. 1983;4(2):199-203.

  48. Murphy MT, Lipton JM. Peripheral administration of alpha-MSH reduces fever in older and younger rabbits. Peptides. 1982;3(5):775-9.

  49. Murphy MT, Richards DB, Lipton JM. Antipyretic potency of centrally administered alpha-melanocyte stimulating hormone. Science. 1983;221(4606):192-3.

  50. Kandasamy SB, Williams BA. Hypothermic and antipyretic effects of ACTH (1-24) and alpha-melanotropin in guinea-pigs. Neuropharmacology. 1984;23(1):49-53.

  51. Shih ST, Lipton JM. Intravenous alpha-MSH reduces fever in the squirrel monkey. Peptides. 1985;6(4):685-7.

  52. Daynes RA, Robertson BA, Cho BH, Burnham DK, Newton R. Alpha-melanocyte-stimulating hormone exhibits target cell selectivity in its capacity to affect interleukin 1-inducible responses in vivo and in vitro. J Immunol. 1987;139(1):103-9.

  53. Deeter LB, Martin LW, Lipton JM. Antipyretic effect of central alpha-MSH summates with that of acetaminophen or ibuprofen. Brain Res Bull. 1989;23(6):573-5.

  54. Martin LW, Lipton JM. Acute phase response to endotoxin: rise in plasma alpha-MSH and effects of alpha-MSH injection. Am J Physiol. 1990;259(4 Pt 2):R768-72.

  55. Feng JD, Dao T, Lipton JM. Effects of preoptic microinjections of alpha-MSH on fever and normal temperature control in rabbits. Brain Res Bull. 1987;18(4):473-7.

  56. Tatro JB 2000 Melanocortin receptor expression and function in the nervous system. In: Cone RD , ed. The melanocortin receptors. Totowa, NJ: Humana Press; 173–207.

  57. Tatro JB 2000 Endogenous antipyretics. Clin Infect Dis 21:S190–S201.

  58. Rezvani AH, Denbow DM, Myers RD. alpha-Melanocyte-stimulating hormone infused ICV fails to affect body temperature or endotoxin fever in the cat. Brain Res Bull. 1986;16(1):99-105.

  59. Greenberg R, Whalley CE, Jourdikian F, Mendelson IS, Walter R, Nikolics K, Coy DH, Schally AV, Kastin AJ 1976 Peptides readily penetrate the blood-brain barrier: uptake of peptides by synaptosomes is passive. PharmacolBiochemBehav 5(Suppl 1):151–158.

  60. Tatro JB, Sinha PS. The central melanocortin system and fever. Ann N Y Acad Sci. 2003;994:246-57.

  61. Sinha PS, Schiöth HB, Tatro JB. Roles of the melanocortin-4 receptor in antipyretic and hyperthermic actions of centrally administered alpha-MSH. Brain Res. 2004;1001(1-2):150-8.

  62. Huang QH, Entwistle ML, Alvaro JD, Duman RS, Hruby VJ, Tatro JB. Antipyretic role of endogenous melanocortins mediated by central melanocortin receptors during endotoxin-induced fever. J Neurosci. 1997;17(9):3343-51.

  63. Han D, Tian Y, Zhang M, Zhou Z, Lu J. Prevention and treatment of experimental autoimmune encephalomyelitis with recombinant adeno-associated virus-mediated alpha-melanocyte-stimulating hormone-transduced PLP139-151-specific T cells. Gene Ther. 2007;14(5):383-95.

  64. Ceriani G, Diaz J, Murphree S, Catania A, Lipton JM. The neuropeptide alpha-melanocyte-stimulating hormone inhibits experimental arthritis in rats. Neuroimmunomodulation. 1994;1(1):28-32.

  65. Taylor AW, Yee DG, Nishida T, Namba K. Neuropeptide regulation of immunity. The immunosuppressive activity of alpha-melanocyte-stimulating hormone (alpha-MSH). Ann N Y Acad Sci. 2000;917:239-47.

  66. Nishida T, Miyata S, Itoh Y, et al. Anti-inflammatory effects of alpha-melanocyte-stimulating hormone against rat endotoxin-induced uveitis and the time course of inflammatory agents in aqueous humor. IntImmunopharmacol. 2004;4(8):1059-66.

  67. Namba K, Kitaichi N, Nishida T, Taylor AW. Induction of regulatory T cells by the immunomodulating cytokines alpha-melanocyte-stimulating hormone and transforming growth factor-beta2. J Leukoc Biol. 2002;72(5):946-52.

  68. Taylor AW, Streilein JW, Cousins SW. Identification of alpha-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. Curr Eye Res. 1992;11(12):1199-206.

  69. Naveh N, Marshall J. Melanocortins are comparable to corticosteroids as inhibitors of traumatic ocular inflammation in rabbits. Graefes Arch ClinExpOphthalmol. 2001;239(11):840-4.

  70. Jahovic N, Arbak S, Tekeli O, Alican I. Alpha-melanocyte stimulating hormone has beneficial effects on cerulein-induced acute pancreatitis. Peptides. 2004;25(1):129-32.

  71. Al-majed HT, Jones PM, Persaud SJ, et al. ACTH stimulates insulin secretion from MIN6 cells and primary mouse and human islets of Langerhans. J Endocrinol. 2004;180(1):155-66.

  72. Jung EJ, Han DJ, Chang SH, et al. Protective effect of alpha-melanocyte-stimulating hormone on pancreas islet cell against peripheral blood mononuclear cell-mediated cytotoxicity in vitro. Transplant Proc. 2007;39(5):1604-6.

  73. Richards, D. B., & Lipton, J. M. (1984). Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit. Peptides, 5(4), 815–817. https://doi.org/10.1016/0196-9781(84)90027-5.

  74. Strand FL, Zuccarelli LA, Williams KA, et al. Melanotropins as growth factors. Ann N Y Acad Sci. 1993;680:29-50.

  75. Gispen WH. The potential of melanotropins in the treatment of nervous system diseases. Ann N Y Acad Sci. 1993;680:401-11.

  76. Gispen WH, Adan RA. Melanocortins and the treatment of nervous system disease. Potential relevance to the skin?. Ann N Y Acad Sci. 1999;885:342-9.

  77. Sharma HS. Neuroprotective effects of neurotrophins and melanocortins in spinal cord injury: an experimental study in the rat using pharmacological and morphological approaches. Ann N Y Acad Sci. 2005;1053:407-21.

  78. Bar PR, Mandys V, Turecek R, Gispen WH. Alpha-melanocyte-stimulating hormone has protective properties against the toxic effect of cisplatin on cultured dorsal root ganglia. Ann N Y Acad Sci. 1993;680:649-51.

  79. Windebank AJ, Smith AG, Russell JW. The effect of nerve growth factor, ciliaryneurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology. 1994;44(3 Pt 1):488-94.

  80. Chai B, Li JY, Zhang W, Newman E, Ammori J, Mulholland MW. Melanocortin-4 receptor-mediated inhibition of apoptosis in immortalized hypothalamic neurons via mitogen-activated protein kinase. Peptides. 2006;27(11):2846-57.

  81. Caruso C, Durand D, Schiöth HB, Rey R, Seilicovich A, Lasaga M. Activation of melanocortin 4 receptors reduces the inflammatory response and prevents apoptosis induced by lipopolysaccharide and interferon-gamma in astrocytes. Endocrinology. 2007;148(10):4918-26.

  82. Bohm M, Wolff I, Scholzen TE, et al. alpha-Melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. J Biol Chem. 2005;280(7):5795-802.

  83. Kadekaro AL, Kavanagh R, Kanto H, et al. alpha-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. Cancer Res. 2005;65(10):4292-9.

  84. Abdel-malek ZA, Kadekaro AL, Kavanagh RJ, et al. Melanoma prevention strategy based on using tetrapeptide alpha-MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity. FASEB J. 2006;20(9):1561-3.

  85. Hill RP, Wheeler P, Macneil S, Haycock JW. Alpha-melanocyte stimulating hormone cytoprotective biology in human dermal fibroblast cells. Peptides. 2005;26(7):1150-8.

  86. Kokot A , Sindrilaru A , Schiller S , Sunderkötter C , Kerkhoff C , Scharffetter-Kochanek K , Luger TA , Böhm M 2008 α-Melanocyte-stimulating hormone is a powerful agent in the bleomycin model of collagen synthesis and fibrosis. ExpDermatol 17:286.

  87. Yamamoto T, Nishioka K. Cellular and molecular mechanisms of bleomycin-induced murine scleroderma: current update and future perspective. ExpDermatol. 2005;14(2):81-95.

  88. Bohm M, Raghunath M, Sunderkötter C, et al. Collagen metabolism is a novel target of the neuropeptide alpha-melanocyte-stimulating hormone. J Biol Chem. 2004;279(8):6959-66.

  89. Lee TH, Jawan B, Chou WY, et al. Alpha-melanocyte-stimulating hormone gene therapy reverses carbon tetrachloride induced liver fibrosis in mice. J Gene Med. 2006;8(6):764-72.

  90. Edwards PM, Van der zee CE, Verhaagen J, Schotman P, Jennekens FG, Gispen WH. Evidence that the neurotrophic actions of alpha-MSH may derive from its ability to mimick the actions of a peptide formed in degenerating nerve stumps. J Neurol Sci. 1984;64(3):333-40.

  91. Vadoudseyedi J, Liénard D, Lespagnard L, Ghanem G, Van wijck R, Lejeune F. Local administration of alpha-MSH exerts a trophic effect on the 200-kDa neurofilament in sciatic rat nerve. Ann N Y Acad Sci. 1993;680:655-9.

  92. Van de meent H, Hamers FP, Lankhorst AJ, Joosten EA, Gispen WH. Beneficial effects of the melanocortin alpha-melanocyte-stimulating hormone on clinical and neurophysiological recovery after experimental spinal cord injury. Neurosurgery. 1997;40(1):122-30.

  93. Lankhorst AJ, Duis SE, Terlaak MP, Joosten EA, Hamers FP, Gispen WH. Functional recovery after central infusion of alpha-melanocyte-stimulating hormone in rats with spinal cord contusion injury. J Neurotrauma. 1999;16(4):323-31.

  94. Joosten EA, Majewska B, Houweling DA, Bär PR, Gispen WH. Alpha-melanocyte stimulating hormone promotes regrowth of injured axons in the adult rat spinal cord. J Neurotrauma. 1999;16(6):543-53.

  95. Sharma HS, Skottner A, Lundstedt T, Flärdh M, Wiklund L. Neuroprotective effects of melanocortins in experimental spinal cord injury. An experimental study in the rat using topical application of compounds with varying affinity to melanocortin receptors. J Neural Transm (Vienna). 2006;113(4):463-76.

  96. Huh SK, Lipton JM, Batjer HH. The protective effects of alpha-melanocyte stimulating hormone on canine brain stem ischemia. Neurosurgery. 1997;40(1):132-9.

  97. Huang Q, Tatro JB. Alpha-melanocyte stimulating hormone suppresses intracerebral tumor necrosis factor-alpha and interleukin-1beta gene expression following transient cerebral ischemia in mice. NeurosciLett. 2002;334(3):186-90.

  98. Spulber S, Moldovan M, Oprica M, et al. Alpha-MSH decreases core and brain temperature during global cerebral ischemia in rats. Neuroreport. 2005;16(1):69-72.

  99. Forslinaronsson S, Spulber S, Popescu LM, et al. alpha-Melanocyte-stimulating hormone is neuroprotective in rat global cerebral ischemia. Neuropeptides. 2006;40(1):65-75.

  100. Giuliani D, Leone S, Mioni C, et al. Broad therapeutic treatment window of [Nle(4), D-Phe(7)]alpha-melanocyte-stimulating hormone for long-lasting protection against ischemic stroke, in Mongolian gerbils. Eur J Pharmacol. 2006;538(1-3):48-56.

  101. Giuliani D, Ottani A, Mioni C, et al. Neuroprotection in focal cerebral ischemia owing to delayed treatment with melanocortins. Eur J Pharmacol. 2007;570(1-3):57-65.

  102. Giuliani D, Mioni C, Altavilla D, et al. Both early and delayed treatment with melanocortin 4 receptor-stimulating melanocortins produces neuroprotection in cerebral ischemia. Endocrinology. 2006;147(3):1126-35.

  103. Vecsernyes M, Juhasz B, Der P, et al. The administration of alpha-melanocyte-stimulating hormone protects the ischemic/reperfused myocardium. Eur J Pharmacol. 2003;470(3):177-83.

  104. Mioni C, Giuliani D , Cainazzo MM, Leone S, Bazzani C, Grieco P, Novellino E, Tomasi A, Bertolini A, Guarini S 2004 Further evidence that melanocortins prevent myocardial reperfusion injury by activating melanocortin MC3 receptors. Eur J Pharmacol 477:227–234.

  105. Bertolini A, Guarini S, Rompianesi E, Ferrari W. Alpha-MSH and other ACTH fragments improve cardiovascular function and survival in experimental hemorrhagic shock. Eur J Pharmacol. 1986;130(1-2):19-26.

  106. Guarini S, Schiöth HB, Mioni C, et al. MC(3) receptors are involved in the protective effect of melanocortins in myocardial ischemia/reperfusion-induced arrhythmias. NaunynSchmiedebergs Arch Pharmacol. 2002;366(2):177-82.

  107. Yamaoka-tojo M, Tojo T, Shioi T, Masuda T, Inomata T, Izumi T. Central neurotranspeptide, alpha-melanocyte-stimulating hormone (alpha-MSH) is upregulated in patients with congestive heart failure. Intern Med. 2006;45(7):429-34.

  108. Chiao H, Kohda Y, Mcleroy P, Craig L, Housini I, Star RA. Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin Invest. 1997;99(6):1165-72

  109. Jo SK, Yun SY, Chang KH, et al. alpha-MSH decreases apoptosis in ischaemic acute renal failure in rats: possible mechanism of this beneficial effect. Nephrol Dial Transplant. 2001;16(8):1583-91.

  110. Kwon TH, Frøkiaer J, Fernández-llama P, Knepper MA, Nielsen S. Reduced abundance of aquaporins in rats with bilateral ischemia-induced acute renal failure: prevention by alpha-MSH. Am J Physiol. 1999;277(3):F413-27.

  111. Gong H, Wang W, Kwon TH, et al. EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int. 2004;66(2):683-95

Other Peptides

Sermorelin

Melanotan 1

Melanotan 2

Tiger 17

Citicoline

Success Stories

men testimonial before after

At the age of 60, I look and feel better than I ever have in my entire life! Switching my health program and hormone replacement therapy regimen over to Genemedics was one of the best decisions I’ve ever made in my life! Genemedics and Dr George have significantly improved my quality of life and also dramatically improved my overall health. I hav...
Nick Cassavetes ,60 yrs old Movie Director (“The Notebook”, “John Q”, “Alpha Dog”), Actor and Writer

See All Men’s Testimonials

Call 800-277-4041 for a Free Consultation

What to expect during your consultation:
  • Usually takes 15-30 minutes
  • Completely confidential
  • No obligation to purchase anything
  • We will discuss your symptoms along with your health and fitness goals
  • Free post-consult access for any additional questions you may have

About

Genemedics® Health Institute is a global premier institute dedicated to revolutionizing health and medicine through healthy lifestyle education, guidance and accountability in harmony with functional medicine. Our physician-supervised health programs are personally customized to help you reach your health and fitness goals while looking and feeling better than ever.

Quick Links

Our Services

 Our Locations

genemedics logo

280 North Old Woodward Ave. Suite 210 Birmingham MI 48009,USA

800-277-4041

info@genemedics.com

© Copyright Genemedics Health Institute. All Rights Reserved. Privacy Policy.

Back to Top
-

Free Consultation

STEPS AWAY FROM A YOUNGER. HEALTHIER YOU!

Call 800-277-4041 for a Free Consultation

What to expect during your consultation:

  • Usually takes 15-30 minutes
  • Completely confidential
  • No obligation to purchase anything
  • We will discuss your symptoms along with your health and fitness goals
  • Free post-consult access for any additional questions you may have
Captch Background